



Saphris® (asenapine) – First-time generic and authorized brand alternative

- On December 11, 2020, [Breckenridge](#), [Alembic](#) and [Sigmapharm](#) launched [AB-rated](#) generic versions of Allergan's [Saphris \(asenapine\)](#) sublingual tablets.
 - In addition, Greenstone launched an authorized brand alternative of Saphris sublingual tablets.
- Saphris is approved for the treatment of schizophrenia in adults and bipolar I disorder.
- Asenapine is also available as a brand transdermal system ([Secuado](#)®).
 - Secuado is approved for the treatment of adults with schizophrenia.
- Saphris carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
- Saphris had annual U.S. sales of \$239 million ending in September 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.